Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. The company generates no product revenue at this stage, operating instead on capital raises while advancing its pipeline toward potential partnering, licensing, or commercialization transactions with third parties. Aclaris uses its proprietary KINect drug discovery platform, which integrates small and large molecule discovery approaches, to identify product candidates designed for superior target affinity, specificity, and potency. As of the 10-K filed February 26, 2026, the company is actively seeking transactions with third-party partners to further develop, obtain regulatory approval for, and commercialize its pipeline. The business is pre-commercial, carrying the capital structure and risk profile typical of clinical-stage biotechnology companies with no approved products generating recurring revenue.

Revenue model

No product revenue disclosed in the filing excerpts. The company is clinical-stage and pursues third-party partnering, licensing, and commercialization transactions as its path to monetization.

Products and services

Novel small and large molecule product candidates targeting immuno-inflammatory diseases, discovered through the proprietary KINect drug discovery platform.

Customers and end markets

Patients with immuno-inflammatory diseases. No commercial customers disclosed in the filing excerpts.

Value-chain role

Drug discovery and early-stage clinical development; seeks downstream partners for late-stage development, regulatory approval, and commercialization.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Innoviva Inc AERIE PHARMACEUTICALS INC Belite Bio Inc Relmada Therapeutics Inc Johnson & Johnson NGM BIOPHARMACEUTICALS INC Pliant Therapeutics Inc REATA PHARMACEUTICALS INC